RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $66

Benzinga · 1d ago
RBC Capital analyst Brian Abrahams maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $66.